ECCO2R with cytokine filtering in COVID-19 patients: Who wants to go down this road?

Abstract

Get full access to this article

View all access options for this article.

References

Shi

Wang

Shao

, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020; 27(5): 1451–1454.

Chen

Zhou

Dong

, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513.

Wang

, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–1069.

Zhou

, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062.

Mahase

Covid-19: demand for dexamethasone surges as RECOVERY trial publishes preprint. BMJ 2020; 369: m2512.

Jeffries

Lund

Frankowski

, et al. An extracorporeal carbon dioxide removal (ECCO₂R) device operating at hemodialysis blood flow rates. Intensive Care Med Exp 2017; 5(1): 41.